These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 21214954)

  • 1. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.
    Fan C; Prat A; Parker JS; Liu Y; Carey LA; Troester MA; Perou CM
    BMC Med Genomics; 2011 Jan; 4():3. PubMed ID: 21214954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
    Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
    Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
    Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
    [No Abstract]   [Full Text] [Related]  

  • 5. Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.
    Zhao X; Rødland EA; Sørlie T; Vollan HK; Russnes HG; Kristensen VN; Lingjærde OC; Børresen-Dale AL
    BMC Cancer; 2014 Mar; 14():211. PubMed ID: 24645668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining gene signatures improves prediction of breast cancer survival.
    Zhao X; Rødland EA; Sørlie T; Naume B; Langerød A; Frigessi A; Kristensen VN; Børresen-Dale AL; Lingjærde OC
    PLoS One; 2011 Mar; 6(3):e17845. PubMed ID: 21423775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.
    Nuyten DS; Hastie T; Chi JT; Chang HY; van de Vijver MJ
    Eur J Cancer; 2008 Oct; 44(15):2319-29. PubMed ID: 18715778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
    Bianchini G; Qi Y; Alvarez RH; Iwamoto T; Coutant C; Ibrahim NK; Valero V; Cristofanilli M; Green MC; Radvanyi L; Hatzis C; Hortobagyi GN; Andre F; Gianni L; Symmans WF; Pusztai L
    J Clin Oncol; 2010 Oct; 28(28):4316-23. PubMed ID: 20805453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach.
    Chowdhury N; Sapru S
    PLoS One; 2015; 10(6):e0129610. PubMed ID: 26080057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
    Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
    Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
    JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
    Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
    Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F4 regulatory program predicts patient survival prognosis in breast cancer.
    Khaleel SS; Andrews EH; Ung M; DiRenzo J; Cheng C
    Breast Cancer Res; 2014 Dec; 16(6):486. PubMed ID: 25440089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
    Pellicane JV; Beitsch PD; Rock DT; Budway RJ; Dul CL; Kelemen PR; Ashikari AY; Baron PL; Weinstein PD; Mislowsky A; Lee LA; Beatty J; Murray MK; Dupree BB; Finn C; Corcoran K; Wang S; Menicucci AR; Yoder EB; Blumencranz LE; Dauer P; Audeh W; Whitworth PW;
    Surg Oncol; 2022 Dec; 45():101885. PubMed ID: 36436423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.